Dear Fellow Investor,
A tiny government task force working out of a strip mall just finished a 20-year mission.
And with almost no media coverage, they confirmed one of the largest U.S. territorial expansions in modern history...
A resource claim worth an estimated $500 trillion.
Thanks to sovereign U.S. law, this isn't just a national asset.
It's an "American birthright".
That means every citizen now has the legal right to stake a "claim"...
But very few even know the opportunity exists.
If you want to see how you can get in line for your portion of this record-breaking windfall...
I've assembled everything you need to see inside a new, time-sensitive briefing:
Get all the details here - while the "claim" window remains open.
"The Buck Stops Here,"
Dylan Jovine, CEO & Founder
Behind the Markets
P.S. This "claim" belongs to American citizens - but the first profits will go to those who move early. See the full briefing here.
ALHC Stock Surges 400%—Here's Why the Bulls Aren't Done
Written by Chris Markoch. First Published: 1/26/2026.
Quick Look
- Alignment Healthcare stock is up more than 400% since April 2024, as improving Medicare Advantage cost trends and disciplined growth have driven a fundamental re-rating.
- ALHC’s value-based care model positions the company to benefit from a Medicare rebound as hospital economics stabilize and utilization normalizes into 2026.
- While ALHC stock remains technically overextended, the bullish trend is intact, with pullbacks toward key support levels offering favorable risk-reward entries.
Alignment Healthcare Inc. (NASDAQ: ALHC) is an example of why even buy-and-hold investors need to leave room for nimble movement. ALHC stock is up more than 58% in the last 12 months and more than 415% since April 2024.
In April 2024, the stock would have qualified as a penny stock, trading around $4.50 per share.
Elon's Out 🚫. Trump's DOGE Payouts Keep Flowing (Up to $32K a Year) (Ad)
DOGE payouts are already moving. Every 90 days, billions flow out — whether you've claimed your share or not. Don't miss your chance.
Click here for the full details.Many investors may have anticipated the move because Alignment Healthcare operates in Medicare Advantage and focuses on value-based care. The company's integrated care model combines in-home clinical services, telehealth capabilities, and digital health tools.
Over the past two years, health insurance stocks—particularly those tied to Medicare Advantage—have posted strong gains, benefiting from scale, pricing power, and a growing senior population.
The Broader Healthcare Trend Is Turning
The Wall Street Journal reports that hospital stocks, which have been beaten down, are expected to rally. Cost inflation is easing, staffing conditions are improving, and reimbursement rates are beginning to stabilize. As these headwinds let up, investor sentiment toward the broader healthcare services ecosystem should improve, including companies tied to Medicare utilization and senior care.
That is why investors can still be bullish on ALHC stock. The company's 18-month rally marks a fundamental reset in how investors view the company's business model.
Medicare Advantage insurers endured a difficult stretch in 2023 and early 2024, driven by higher medical costs and reimbursement uncertainty. However, Alignment began demonstrating tangible progress in controlling expenses—medical cost trends improved, risk-adjustment capture strengthened, and management shifted toward more disciplined growth.
That efficiency appears to have convinced investors that Alignment's value-based care strategy can scale profitably. Just as important, that period offered investors leveraged exposure to a potential Medicare rebound, since much of the bad news had already been priced in.
As fears around margin compression have faded, the stock has benefited from both a fundamental re-rating and technical tailwinds, including short covering and renewed interest in mid-cap healthcare names. If hospital economics and Medicare utilization continue to normalize as expected in 2026, Alignment's integrated care model and mid-cap positioning could make the company a beneficiary of improving industry conditions.
ALHC Stock Looks Overbought, But the Uptrend Is Intact
Despite the reasons to own ALHC, now might not be the ideal entry point. ALHC is technically extended, with the stock pushing to new 52‑week highs and trading well above key moving averages—signs of a strong but stretched uptrend.
The daily RSI in the low‑70s and a strongly positive MACD indicate overbought momentum rather than a low‑risk entry, so chasing at current levels offers poor risk‑reward even though the longer-term trend remains bullish.
A better approach for investors on the sidelines is to stay constructive on the name but wait for a pullback into defined support zones. The first buy zone is around $21.50 to $22.00—an area of recent consolidation just below the highs where an initial bounce would favor more aggressive entries.
A more conservative, higher‑probability zone is $20.25–$20.75, near the rising 50‑day moving average and the prior base. If the stock can hold these levels, it would confirm trend integrity. Traders could scale in around the upper zone and add closer to the 50‑day, using a stop just below the 20‑day SMA to define risk, while targeting a retest and modest extension of the highs in the $24–$25 region so long as pullbacks remain orderly and support holds.
This email message is a sponsored email from Behind the Markets, a third-party advertiser of MarketBeat. Why did I get this email content?.
If you have questions or concerns about your subscription, please email our South Dakota based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
Copyright 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Place #620, Sioux Falls, S.D. 57103. USA..
Post a Comment
Post a Comment